5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Risk O
of O
bleeding O
: O
XARELTO O
can O
cause O
serious O
and O
fatal O
bleeding O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.2 O
) O
* O
Pregnancy-related O
hemorrhage O
: O
Use O
XARELTO O
with O
caution O
in O
pregnant O
women O
due O
to O
the O
potential O
for O
obstetric O
hemorrhage O
and/or O
emergent O
delivery O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.7 O
) O
* O
Prosthetic O
heart O
valves O
: O
XARELTO O
use O
not O
recommended O
( O
5.8 O
) O
5.1 O
Increased O
Risk O
of O
Thrombotic O
Events O
after O
Premature O
Discontinuation O
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
in O
the O
absence O
of O
adequate O
alternative O
anticoagulation O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

An O
increased O
rate O
of O
stroke B-NonOSE_AE
was O
observed O
during O
the O
transition O
from O
XARELTO O
to O
warfarin O
in O
clinical O
trials O
in O
atrial B-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
patients O
. O

If O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding B-NonOSE_AE
or O
completion O
of O
a O
course O
of O
therapy O
, O
consider O
coverage O
with O
another O
anticoagulant O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
, O
2.8 O
) O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.2 O
Risk O
of O
Bleeding O
XARELTO O
increases O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
and O
can O
cause O
serious O
or O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
. O

In O
deciding O
whether O
to O
prescribe O
XARELTO O
to O
patients O
at O
increased O
risk O
of O
bleeding B-NonOSE_AE
, O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
should O
be O
weighed O
against O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

Promptly O
evaluate O
any O
signs O
or O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
and O
consider O
the O
need O
for O
blood O
replacement O
. O

Discontinue O
XARELTO O
in O
patients O
with O
active O
pathological O
hemorrhage B-Not_AE_Candidate
. O

The O
terminal O
elimination O
half-life O
of O
rivaroxaban O
is O
5 O
to O
9 O
hours O
in O
healthy O
subjects O
aged O
20 O
to O
45 O
years O
. O

Concomitant O
use O
of O
other O
drugs O
that O
impair B-NonOSE_AE
hemostasis I-NonOSE_AE
increases O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

These O
include O
aspirin O
, O
P2Y12platelet O
inhibitors O
, O
other O
antithrombotic O
agents O
, O
fibrinolytic O
therapy O
, O
non-steroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
, O
selective O
serotonin O
reuptake O
inhibitors O
, O
and O
serotonin O
norepinephrine O
reuptake O
inhibitors O
. O

Concomitant O
use O
of O
drugs O
that O
are O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inhibitors O
increases O
rivaroxaban O
exposure O
and O
may O
increase O
bleeding B-NonOSE_AE
risk O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Reversal O
of O
Anticoagulant O
Effect O
A O
specific O
antidote O
for O
rivaroxaban O
is O
not O
available O
. O

Because O
of O
high O
plasma O
protein O
binding O
, O
rivaroxaban O
is O
not O
expected O
to O
be O
dialyzable O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Protamine O
sulfate O
and O
vitamin O
K O
are O
not O
expected O
to O
affect O
the O
anticoagulant O
activity O
of O
rivaroxaban O
. O

Partial O
reversal O
of O
prothrombin O
time O
prolongation O
has O
been O
seen O
after O
administration O
of O
prothrombin O
complex O
concentrates O
( O
PCCs O
) O
in O
healthy O
volunteers O
. O

The O
use O
of O
other O
procoagulant O
reversal O
agents O
like O
activated O
prothrombin O
complex O
concentrate O
( O
APCC O
) O
or O
recombinant O
factor O
VIIa O
( O
rFVIIa O
) O
has O
not O
been O
evaluated O
. O

5.3 O
Spinal/Epidural O
Anesthesia O
or O
Puncture O
When O
neuraxial B-Not_AE_Candidate
anesthesia I-Not_AE_Candidate
( O
spinal B-Not_AE_Candidate
/epidural O
anesthesia I-Not_AE_Candidate
) O
or O
spinal O
puncture O
is O
employed O
, O
patients O
treated O
with O
anticoagulant O
agents O
for O
prevention B-Not_AE_Candidate
of I-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
complications I-Not_AE_Candidate
are O
at O
risk O
of O
developing O
an O
epidural B-OSE_Labeled_AE
or O
spinal O
hematoma I-OSE_Labeled_AE
which O
can O
result O
in O
long-term O
or O
permanent O
paralysis B-NonOSE_AE
[ O
see O
Boxed O
Warning O
] O
. O

To O
reduce O
the O
potential O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concurrent O
use O
of O
XARELTO O
and O
epidural B-NonOSE_AE
or O
spinal O
anesthe O
sia B-NonOSE_AE
/ I-NonOSE_AE
analgesia I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
NonOSE_AE O
or O
spinal O
puncture O
, O
consider O
the O
pharmacokinetic O
profile O
of O
XARELTO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Placement O
or O
removal O
of O
an O
epidural O
catheter O
or O
lumbar O
puncture O
is O
best O
performed O
when O
the O
anticoagulant O
effect O
of O
XARELTO O
is O
low O
; O
however O
, O
the O
exact O
timing O
to O
reach O
a O
sufficiently O
low O
anticoagulant O
effect O
in O
each O
patient O
is O
not O
known O
. O

An O
indwelling O
epidural O
or O
intrathecal O
catheter O
should O
not O
be O
removed O
before O
at O
least O
2 O
half-lives O
have O
elapsed O
( O
i.e. O
, O
18 O
hours O
in O
young O
patients O
aged O
20 O
to O
45 O
years O
and O
26 O
hours O
in O
elderly O
patients O
aged O
60 O
to O
76 O
years O
) O
, O
after O
the O
last O
administration O
of O
XARELTO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

The O
next O
XARELTO O
dose O
should O
not O
be O
administered O
earlier O
than O
6 O
hours O
after O
the O
removal O
of O
the O
catheter O
. O

If O
traumatic O
puncture O
occurs O
, O
delay O
the O
administration O
of O
XARELTO O
for O
24 O
hours O
. O

Should O
the O
physician O
decide O
to O
administer O
anticoagulation O
in O
the O
context O
of O
epidural B-NonOSE_AE
or O
spinal O
anesthesia I-NonOSE_AE
/analgesia O
or O
lumbar O
puncture O
, O
monitor O
frequently O
to O
detect O
any O
signs O
or O
symptoms O
of O
neurological B-NonOSE_AE
impairment I-NonOSE_AE
, O
such O
as O
midline B-NonOSE_AE
back I-NonOSE_AE
pain I-NonOSE_AE
, O
sensory B-NonOSE_AE
and O
motor O
deficits I-NonOSE_AE
( O
numbness B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
in I-NonOSE_AE
lower I-NonOSE_AE
limbs I-NonOSE_AE
) O
, O
bowel B-NonOSE_AE
and/or O
bladder O
dysfunction I-NonOSE_AE
. O

Instruct O
patients O
to O
immediately O
report O
if O
they O
experience O
any O
of O
the O
above O
signs O
or O
symptoms O
. O

If O
signs O
or O
symptoms O
of O
spinal B-NonOSE_AE
hematoma I-NonOSE_AE
are O
suspected O
, O
initiate O
urgent O
diagnosis O
and O
treatment O
including O
consideration O
for O
spinal B-NonOSE_AE
cord I-NonOSE_AE
decompression I-NonOSE_AE
even O
though O
such O
treatment O
may O
not O
prevent O
or O
reverse O
neurological B-NonOSE_AE
sequelae I-NonOSE_AE
. O

5.4 O
Use O
in O
Patients O
with O
Renal O
Impairment O
Nonvalvular O
Atrial O
Fibrillation O
Periodically O
assess O
renal O
function O
as O
clinically O
indicated O
( O
i.e. O
, O
more O
frequently O
in O
situations O
in O
which O
renal B-NonOSE_AE
function I-NonOSE_AE
may I-NonOSE_AE
decline I-NonOSE_AE
) O
and O
adjust O
therapy O
accordingly O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Consider O
dose O
adjustment O
or O
discontinuation O
of O
XARELTO O
in O
patients O
who O
develop O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
while O
on O
XARELTO O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Treatment O
of O
Deep O
Vein O
Thrombosis O
( O
DVT O
) O
, O
Pulmonary O
Embolism O
( O
PE O
) O
, O
and O
Reduction O
in O
the O
Risk O
of O
Recurrence O
of O
DVT O
and O
of O
PE O
Avoid O
the O
use O
of O
XARELTO O
in O
patients O
with O
CrCl B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
due O
to O
an O
expected O
increase O
in O
rivaroxaban O
exposure O
and O
pharmacodynamic O
effects O
in O
this O
patient O
population O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Prophylaxis O
of O
Deep O
Vein O
Thrombosis O
Following O
Hip O
or O
Knee O
Replacement O
Surgery O
Avoid O
the O
use O
of O
XARELTO O
in O
patients O
with O
CrCl B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
due O
to O
an O
expected O
increase O
in O
rivaroxaban O
exposure O
and O
pharmacodynamic O
effects O
in O
this O
patient O
population O
. O

Observe O
closely O
and O
promptly O
evaluate O
any O
signs O
or O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
in O
patients O
with O
CrCl B-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
. O

Patients O
who O
develop O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
while O
on O
XARELTO O
should O
discontinue O
the O
treatment O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.5 O
Use O
in O
Patients O
with O
Hepatic O
Impairment O
No O
clinical O
data O
are O
available O
for O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Avoid O
use O
of O
XARELTO O
in O
patients O
with O
moderate O
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
and O
severe O
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
C I-Not_AE_Candidate
) O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
with O
any O
hepatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
coagulopathy I-Not_AE_Candidate
since O
drug O
exposure O
and O
bleeding B-NonOSE_AE
risk O
may O
be O
increased O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
] O
. O

5.6 O
Use O
with O
P-gp O
and O
Strong O
CYP3A4 O
Inhibitors O
or O
Inducers O
Avoid O
concomitant O
use O
of O
XARELTO O
with O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inhibitors O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Avoid O
concomitant O
use O
of O
XARELTO O
with O
drugs O
that O
are O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inducers O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.7 O
Risk O
of O
Pregnancy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
In O
pregnant B-Not_AE_Candidate
women O
, O
XARELTO O
should O
be O
used O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the O
mother O
and O
fetus I-NonOSE_AE
. O

XARELTO O
dosing O
in O
pregnancy B-Not_AE_Candidate
has O
not O
been O
studied O
. O

The O
anticoagulant O
effect O
of O
XARELTO O
can O
not O
be O
monitored O
with O
standard O
laboratory O
testing O
nor O
readily O
reversed O
. O

Promptly O
evaluate O
any O
signs O
or O
symptoms O
suggesting O
blood B-NonOSE_AE
loss I-NonOSE_AE
( O
e.g. O
, O
a O
drop B-NonOSE_AE
in I-NonOSE_AE
hemoglobin O
and/or O
hematocrit I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
or O
fetal B-NonOSE_AE
distress I-NonOSE_AE
) O
. O

5.8 O
Patients O
with O
Prosthetic O
Heart O
Valves O
The O
safety O
and O
efficacy O
of O
XARELTO O
have O
not O
been O
studied O
in O
patients O
with O
prosthetic O
heart O
valves O
. O

Therefore O
, O
use O
of O
XARELTO O
is O
not O
recommended O
in O
these O
patients O
. O

5.9 O
Acute O
PE O
in O
Hemodynamically O
Unstable O
Patients O
or O
Patients O
Who O
Require O
Thrombolysis O
or O
Pulmonary O
Embolectomy O
Initiation O
of O
XARELTO O
is O
not O
recommended O
acutely O
as O
an O
alternative O
to O
unfractionated O
heparin O
in O
patients O
with O
pulmonary B-Not_AE_Candidate
embolism I-Not_AE_Candidate
who O
present O
with O
hemodynamic B-Not_AE_Candidate
instability I-Not_AE_Candidate
or O
who O
may O
receive O
thrombolysis B-Not_AE_Candidate
or O
pulmonary O
embolectomy O
. O

